8-K - Outlook Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Outlook Therapeutics entered into a Note Purchase Agreement with Atlas Sciences, LLC, issuing an unsecured promissory note with $18.36 million principal for $17 million purchase price to partially repay its existing $33.1 million Avondale convertible note, leaving approximately $10.8 million outstanding. The Avondale note's maturity was extended to December 31, 2026, amid supplemental risk factors highlighting going concern doubts.

Key Takeaways

1Issued unsecured promissory note to Atlas Sciences, LLC with original principal $18,360,000 and $1,360,000 OID for $17,000,000 purchase price on March 16, 2026.

2Proceeds used solely for $17,000,000 partial repayment of Avondale convertible note dated March 13, 2025 (original principal $33,100,000), leaving $10,806,991 remaining.

3New note interest at prime rate plus 3% (floor 9.5%), matures 15 months after closing (June 2027), with Investor redemption right up to $3,000,000 per quarter starting six months post-closing.

4All cash payments on new note subject to 7.5% exit fee.

5Avondale note amended to extend maturity to December 31, 2026.

6Company covenants include no asset encumbrances (with exceptions), no restricted issuances without consent, and maintenance of Nasdaq listing.

Current Report Details

Event Type

Material Agreement

Financing

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) wit

Material Agreement

$18.4M$1.4M$17.0M$17.0M

Source Document

2.03

by reference. Item 8.01 Other Events. In connection with entry into the Note, the Company is providing supplemental risk factors, which are filed herewith as Ex

Financing

9.01

Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 10.1 Note Purchase Agreement, dated March 16, 2026, by and between the Company and Atlas

Exhibits Only

Source Document

Transaction Details

Material Agreement

Agreement: Note Purchase Agreement
Parties: Outlook Therapeutics, Inc., Atlas Sciences, LLC

•Unsecured promissory note issuance with original principal $18,360,000 and purchase price $17,000,000.
•Proceeds solely for partial repayment of Avondale Note.
•Covenants: timely SEC filings, maintain Nasdaq listing, no asset/IP encumbrances without consent, no restricted issuances without consent.
•Closing occurred March 16, 2026.

Debt / Financing

Instrument: Unsecured Promissory Note
Principal: 18360000
Rate: prime rate (Wall Street Journal) plus 3% (floor 9.5%)
Maturity: 15 months after March 16, 2026
Use of Proceeds: Partial repayment of $17,000,000 on Avondale convertible promissory note (original principal $33,100,000 dated March 13, 2025).

Exhibits (5)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

10.3

EXHIBIT 10.3

8-K

FORM 8-K

99.1

EXHIBIT 99.1